TMPRSS2 and COVID-19: Since remdesivir has been shown to reduce hospitalization [19] and may reduce mortality in patients with severe COVID-19 infection [41], we hypothesized that suppression of viral entry into cells through inhibition of ACE2 and TMPRSS2 would reduce the spread of SARS-CoV-2 infection in a given COVID-19-(+) patient and this would allow the innate immune system and antivirals such as remdesivir to more effectively suppress early infection.